OBJECTIVE: To determine if implementation of 2010 World Health Organization (WHO) guidelines on antiretroviral therapy (ART) initiation reduced delay from tuberculosis diagnosis to initiation of ART in a Cambodian urban hospital. METHODS: A retrospective cohort study was conducted in a nongovernmental hospital in Phnom Penh that followed new WHO guidelines in patients with human immunodeficiency virus (HIV) and tuberculosis. All ART-naïve, HIV-positive patients initiated on antituberculosis treatment over the 18 months before and after guideline implementation were included. A competing risk regression model was used. FINDINGS: After implementation of the 2010 WHO guidelines, 190 HIV-positive patients with tuberculosis were identified: 53% males; median age, 38 years; median baseline CD4+ T-lymphocyte (CD4+ cell) count, 43 cells/µL. Before implementation, 262 patients were identified; 56% males; median age, 36 years; median baseline CD4+ cell count, 59 cells/µL. With baseline CD4+ cell counts ≤ 50 cells/µL, median delay to ART declined from 5.8 weeks (interquartile range, IQR: 3.7-9.0) before to 3.0 weeks (IQR: 2.1-4.4) after implementation (P < 0.001); with baseline CD4+ cell counts > 50 cells/µL, delay dropped from 7.0 (IQR: 5.3-11.3) to 3.6 (IQR: 2.9-5.3) weeks (P < 0.001). The probability of ART initiation within 4 and 8 weeks after tuberculosis diagnosis rose from 23% and 65%, respectively, before implementation, to 62% and 90% after implementation. A non-significant increase in 6-month retention and antiretroviral substitution was seen after implementation. CONCLUSION: Implementation of 2010 WHO recommendations in a routine clinical setting shortens delay to ART. Larger studies with longer follow-up are needed to assess impact on patient outcomes.
OBJECTIVE: To determine if implementation of 2010 World Health Organization (WHO) guidelines on antiretroviral therapy (ART) initiation reduced delay from tuberculosis diagnosis to initiation of ART in a Cambodian urban hospital. METHODS: A retrospective cohort study was conducted in a nongovernmental hospital in Phnom Penh that followed new WHO guidelines in patients with human immunodeficiency virus (HIV) and tuberculosis. All ART-naïve, HIV-positivepatients initiated on antituberculosis treatment over the 18 months before and after guideline implementation were included. A competing risk regression model was used. FINDINGS: After implementation of the 2010 WHO guidelines, 190 HIV-positivepatients with tuberculosis were identified: 53% males; median age, 38 years; median baseline CD4+ T-lymphocyte (CD4+ cell) count, 43 cells/µL. Before implementation, 262 patients were identified; 56% males; median age, 36 years; median baseline CD4+ cell count, 59 cells/µL. With baseline CD4+ cell counts ≤ 50 cells/µL, median delay to ART declined from 5.8 weeks (interquartile range, IQR: 3.7-9.0) before to 3.0 weeks (IQR: 2.1-4.4) after implementation (P < 0.001); with baseline CD4+ cell counts > 50 cells/µL, delay dropped from 7.0 (IQR: 5.3-11.3) to 3.6 (IQR: 2.9-5.3) weeks (P < 0.001). The probability of ART initiation within 4 and 8 weeks after tuberculosis diagnosis rose from 23% and 65%, respectively, before implementation, to 62% and 90% after implementation. A non-significant increase in 6-month retention and antiretroviral substitution was seen after implementation. CONCLUSION: Implementation of 2010 WHO recommendations in a routine clinical setting shortens delay to ART. Larger studies with longer follow-up are needed to assess impact on patient outcomes.
Authors: S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood Journal: Int J Tuberc Lung Dis Date: 2011-05 Impact factor: 2.373
Authors: R Zachariah; K Tayler-Smith; M Manzi; M Massaquoi; B Mwagomba; J van Griensven; I van Engelgem; L Arnould; E J Schouten; F M Chimbwandira; A D Harries Journal: Trans R Soc Trop Med Hyg Date: 2011-07-02 Impact factor: 2.184
Authors: Anthony D Harries; Rony Zachariah; Elizabeth L Corbett; Stephen D Lawn; Ezio T Santos-Filho; Rhehab Chimzizi; Mark Harrington; Dermot Maher; Brian G Williams; Kevin M De Cock Journal: Lancet Date: 2010-05-18 Impact factor: 79.321
Authors: R A Murphy; H Sunpath; B Taha; S Kappagoda; K T M Maphasa; D R Kuritzkes; L Smeaton Journal: Int J Tuberc Lung Dis Date: 2010-07 Impact factor: 2.373
Authors: Stephen D Lawn; Lucy Campbell; Richard Kaplan; Andrew Boulle; Morna Cornell; Bernhard Kerschberger; Carl Morrow; Francesca Little; Matthias Egger; Robin Wood Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Nwarbébé Barnabas Njozing; San Sebastian Miguel; Pius Muffih Tih; Anna-Karin Hurtig Journal: BMC Public Health Date: 2010-03-12 Impact factor: 3.295
Authors: Olivier Koole; Sopheak Thai; Kim Eam Khun; Reaksmey Pe; Johan van Griensven; Ludwig Apers; Jef Van den Ende; Tan Eang Mao; Lutgarde Lynen Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Haileyesus Getahun; Wanitchaya Kittikraisak; Charles M Heilig; Elizabeth L Corbett; Helen Ayles; Kevin P Cain; Alison D Grant; Gavin J Churchyard; Michael Kimerling; Sarita Shah; Stephen D Lawn; Robin Wood; Gary Maartens; Reuben Granich; Anand A Date; Jay K Varma Journal: PLoS Med Date: 2011-01-18 Impact factor: 11.069
Authors: Matthew D Hickey; Thomas A Odeny; Maya Petersen; Torsten B Neilands; Nancy Padian; Nathan Ford; Zachary Matthay; David Hoos; Meg Doherty; Chris Beryer; Stefan Baral; Elvin H Geng Journal: Implement Sci Date: 2017-08-08 Impact factor: 7.327